Lupin gets USFDA nod to market oral contraceptives

The drug had US sales of $89.8 million as per Sept 2015 sales data

Drug major Lupin has received final approval from the US health regulator to market generic version of Warner Chilcott's oral contraceptive Generess Fe in the American market.

In a BSE filing, Lupin said it "has received final approval for its Kaitlib Fe Tablets from the United States Food and Drug Administration (USFDA) to market Warner Chilcott's Generess Fe Chewable Tablets", Lupin said in a BSE filing.

Quoting IMS MAT September 2015 sales data, Lupin said the tablets had US sales of $89.8 million.

The Mumbai-based firm has launched nine products in the US market and received approvals for 20 products from the USFDA so far this fiscal.
 

The company added that its US subsidiary Lupin Pharmaceuticals Inc will commence promoting the product in the US shortly.

Lupin stock closed 0.17 per cent down at Rs 1,715.35 on BSE.